NCT00006617View on ClinicalTrials.gov

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

NACompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

Not specified

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

HIV Infections

Interventions

DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Lamivudine

DRUG

Zidovudine

Trial Locations (1)

10016

Aaron Diamond AIDS Res Ctr, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00006617 - Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients | Biotech Hunter | Biotech Hunter